Radiologists are drowning. Imaging backlogs are piling up like email in your spam folder, and hospitals are hemorrhaging time and money trying to keep up. Meanwhile, Aidoc isn’t just tossing them a life vest, it’s building a battleship.
Founded in 2016 by three Talpiot alums who cut their teeth decoding airborne imaging data in Israel’s military intelligence scene, Aidoc has since evolved into the most FDA-cleared clinical AI company on the planet. And as of July 23, it just locked in a $150 million growth round, $110 million in equity, $40 million in revolving credit, from General Catalyst and Square Peg Capital. Add NVentures (yeah, that’s NVIDIA’s venture arm) plus strategic checks from Hartford HealthCare, Mercy, Sutter Health, and WellSpan Health, and you’ve got a syndicate that reads like a who’s-who of people betting on the future of real healthcare delivery, not just another AI demo.
Let’s get real: clinical AI isn’t about building yet another chatGPT-for-doctors clone, it’s about impact. Aidoc’s aiOS platform isn’t just a tool, it’s infrastructure. It stitches together imaging data, EHR records, and hospital workflows to surface critical findings when they actually matter. With over 20 FDA-cleared algorithms, 1,200+ hospitals deployed, and 45 million patients touched annually, this is less of a startup story and more of an operating system rollout.
And now there’s CARE, Aidoc’s new Clinical AI Reasoning Engine. This foundation model isn’t playing catch-up. It’s already analyzing multimodal data across radiology, neuro, vascular, and cardiovascular pathologies, and accelerating new product development by a factor of 20. That’s not scale. That’s force-multiplication.
Huge shoutout to Co-founder and CEO Elad Walach, Co-founder and CTO Michael Braginsky, and Co-founder and Chief Architect Guy Reiner. These guys didn’t just build a product, they architected a platform that’s finally giving overstretched care teams the superpowers they deserve. With President & CCO Dr. Aswin Chandrakantan pushing commercial growth and Chief Product Officer Reut Yalon, PhD driving roadmap execution, this team isn’t playing defense. They’re already 20 moves ahead.
Next up? Expanding into oncology and cardiovascular AI, doubling down on high-performance compute with NVIDIA and AWS, and onboarding more third-party models to their open aiOS ecosystem. Because when 69% of your customers are already running non-Aidoc models on your platform, you’re not just building for yourself, you’re building for the future of medicine.
